Grail
Grail Launches Galleri Cancer Early Detection Test, Backed by First PATHFINDER Interventional Data
Premium
The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
In Brief This Week: Merck, Clovis Oncology, Grail, GenomOncology, Veracyte, Amoy Diagnostics
News items for the week of March 15, 2021.Â
Strata Oncology Launches Large Study Eyeing Competitive Cancer Monitoring, Drug Selection Test Space
Premium
The firm will begin a 100,000-patient study of its investigational liquid biopsy assay that could help bring targeted therapies into earlier lines of treatment.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
Sep 21, 2020
Illumina to Acquire Grail for $8B in Cash and Stock
Apr 29, 2020
Oct 1, 2019
ESMO 2019 Precision Oncology Highlights
May 10, 2019
Apr 1, 2019
Jun 5, 2018